Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.

Publication date: May 29, 2026

Long COVID is increasingly recognized as a complex multisystem condition, with brain fog and cognitive impairment emerging as some of its manifestations. Despite growing literature, the pooled prevalence, subgroup differences, and underlying mechanisms remain incompletely understood. We systematically reviewed 47 studies (2000-2025) encompassing over 25,000 patients to evaluate the prevalence of brain fog and cognitive impairment among long COVID populations. Data were extracted on study design, patient demographics, follow-up duration, and subgroup variables including gender, hospitalization, vaccination, and geographic region. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS v9. 0) and JBI checklists. Quantitative synthesis was performed with subgroup and temporal analyses, presented in forest plots and summary figures. The pooled prevalence of brain fog was 30% (95% CI: 28-32), while cognitive impairment was 25% (95% CI: 23-27). Female patients consistently showed higher rates compared to males (34% vs 23% for brain fog; 29% vs 21% for cognitive impairment). Community-managed patients demonstrated higher prevalence compared to hospitalized cohorts, and unvaccinated individuals had a greater burden than vaccinated ones. Temporal analyses indicated that prevalence increased with longer follow-up, suggesting symptom persistence or late manifestation. Pathophysiological explanations include neuroinflammation, microvascular injury, immune dysregulation, and psychosocial stressors. Brain fog and cognitive impairment are common, persistent, and clinically significant features of long COVID. Gender differences, vaccination status, and follow-up duration influence prevalence. Future studies should focus on mechanisms, preventive strategies, and targeted interventions to mitigate long-term cognitive sequelae.

Open Access PDF

Concepts Keywords
Covid brain fog
Neuroinflammation Cognitive Dysfunction
Ottawa cognitive impairment
COVID-19
Female
Humans
Long COVID
Male
neuroinflammation
Post-Acute COVID-19 Syndrome
post-acute sequelae
Prevalence
SARS-CoV-2

Semantics

Type Source Name
disease MESH brain fog
disease MESH cognitive impairment
disease MESH long COVID
disease MESH neuroinflammation
disease MESH injury
disease MESH Long Covid brain fog
disease MESH COVID-19

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *